Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025)

Fennec Pharmaceuticals (FENC) has 3 years of Cost of Revenue data on file, last reported at $6.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cost of Revenue rose 54.82% year-over-year to $6.1 million; the trailing twelve-month figure through Dec 2025 stood at $12.7 million (up 20.27% YoY), and the FY2025 full-year result was $18.6 million, up 1.03% from the prior year.
• Cost of Revenue for Q4 2025 stood at $6.1 million, up from $5.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $6.1 million in Q4 2025 and bottomed at $95000.0 in Q1 2023.
• The 3-year median for Cost of Revenue is $2.9 million (2023), against an average of $2.7 million.
• The widest annual swing landed in 2024, when Cost of Revenue surged 478.95%; it then tumbled 79.3% in 2025.
• A 3-year view of Cost of Revenue shows it stood at $3.9 million in 2023, then grew by 1.96% to $3.9 million in 2024, then soared by 54.82% to $6.1 million in 2025.
• The last three Cost of Revenue figures came in at $6.1 million (Q4 2025), $5.2 million (Q3 2025), and $967000.0 (Q2 2025), per Business Quant data.

Peer Comparison